PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
David Bumcrot	04/25/2012
Ivanka Toudjarska	05/31/2012
Jared Gollob	06/29/2012
Akshay Vaishnaw	05/29/2012
Dinah Wen-Yee Sah	04/28/2012
Christina Gamba-Vitalo	04/26/2012

RECEIVING PARTY DATA

Name:	Alnylam Pharmaceuticals, Inc.
Street Address:	300 Third Street
City:	Cambridge
State/Country:	MASSACHUSETTS
Postal Code:	02142

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13496196

CORRESPONDENCE DATA

Fax Number: (650)938-5200 Phone: (415) 875-2316 Email: nmorad@fenwick.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Susan T. Hubl Address Line 1: Fenwick & West LLP Address Line 2: 801 California Street

Address Line 4: Mountain View, CALIFORNIA 94041

ATTORNEY DOCKET NUMBER: 17331 US

REEL: 028479 FRAME: 0841

PATENT

501976225

NAME OF SUBMITTER:	Susan T. Hubl, Reg. 47,668
Total Attachments: 5 source=17331_Assignment#page1.tif source=17331_Assignment#page2.tif source=17331_Assignment#page3.tif source=17331_Assignment#page4.tif source=17331_Assignment#page5.tif	

PATENT REEL: 028479 FRAME: 0842

<u>ASSIGNMENT</u>

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to **Alnylam Pharmaceuticals, Inc.**, a Delaware corporation, having a place of business at 300 Third Street, Cambridge, MA 02142, ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

- 1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):
 - U.S. Application No. 13/496,196, entitled "Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes," which is a National Phase Entry of International Application No. PCT/US2010/048512, filed on September 10, 2010, which claims priority from which claims priority from a provisional application filed on September 15, 2009, now bearing U.S. Application No. 61/242,693, and from a provisional application filed on September 22, 2009, now bearing U.S. Application No. 61/244,792, and from a provisional application filed on October 28, 2009, now bearing US Application No. 61/255,692, and from a provisional application filed on November 17, 2009, now bearing U.S. Application No. 61/262,046, and from a provisional application filed on April 20, 2010, now bearing U.S. Application No. 61/326,071, and from a provisional application filed on June 7, 2010, now bearing U.S. Application No. 61/352,128.
- 2. The entire worldwide right, title, and interest in and to:
 (a) the APPLICATION; (b) all applications claiming priority from the APPLICATION;
 (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths,

Attorney Docket No: 26421-17331 US

ALN-094 US

1 of 3

Title:

Lipid Formulated Compositions And Methods For Inhibiting Expression

Of Eg5 And VEGF Genes

I.A. Filing Date:

September 10, 2010

Application No.:

13/496,196

assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature	Date of Signature
David Bumcrot	Apr. 25, 2012, 2012
Name and Signature	Date of Signature
	, 2012
Dinah Wen-Yee Sah	
Name and Signature	Date of Signature
worth	May, 31, 2012
Ivanka Toudjarska	

Attorney Docket No: 26421-17331 US ALN-094 US

2 of 3

Title:	Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes	
I.A. Filing Date: Application No.:	September 10, 2010 13/496,196	
Name and Signature	Date of Signature 6/29, 2012	
Name and Signature	Date of Signature	
Akshay Vaishnaw Name and Signature	Date of Signature	
Christina Gamba Vitalo	, 2012	

Attorney Docket No; 26421-17331 US ALN-094 US

26421/17331/DOCS/2648700,1

3 of 3

PATENT REEL: 028479 FRAME: 0845 Title:

Lipid Formulated Compositions And Methods For Inhibiting Expression

Of Eg5 And VEGF Genes

1.A. Filing Date:

September 10, 2010

Application No.: 13/496,196

assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature	Date of Signature
	, 2012
David Bumcrot	
Name and Signature	Date of Signature
Dinah Wen-Yee Sah	April 28, 2012
Dinah Wen-Yee Sah	
Name and Signature	Date of Signature
	, 2012
Ivanka Toudjarska	

Attorney Docket No: 26421-17331 US

ALN-094 US

2 of 3

Title:	Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes
I.A. Filing Date:	September 10, 2010
Application No.:	13/496,196
Name and Signature	Date of Signature
	, 2012
Jared Gollob	
Name and Signature	Date of Signature
	, 2012
Akshay Vaishnaw	
Name and Signature	Date of Signature
Christina gamba Ve	tato 26 April ,2012
Ct	U t

Attorney Docket No: 26421-17331 US ALN-094 US

26421/17331/DOCS/2648700.1

3 of 3

PATENT REEL: 028479 FRAME: 0847